VXRT Vaxart Inc
75,357
$0.7337
$0.0325
(4.24%)
| Watchers | 75,357 |
| 52-Wk Low | $0.53 |
| 52-Wk High | $1.59 |
| Market Cap | $135.49M |
| Volume | 412,370.00 |
| 52-Wk High | $1.59 |
| 52-Wk Low | $0.53 |
Vaxart to Present at World Vaccine Congress Washington 2024 on April 3Globe Newswire • about 1 month ago
SOUTH SAN FRANCISCO, Calif., March 27, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) today announced that Dr. Sean Tucker, Founder and Chief Scientific Officer, will present at the World...
Share to Feed
Vaxart, Inc. (NASDAQ:VXRT Free Report) Equities research analysts at B. Riley issued their Q1 2024 earnings estimates for shares of Vaxart in a research note issued on Wednesday...
Vaxart, Inc. (NASDAQ:VXRT Free Report) Equities researchers at B. Riley issued their Q2 2024 earnings estimates for shares of Vaxart in a note issued to investors on Wednesday, March...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
SOUTH SAN FRANCISCO, Calif., March 20, 2024 (GLOBE NEWSWIRE) -- Vaxart, Inc. (Nasdaq: VXRT) (the Company or Vaxart ) today announced that the Compensation Committee of the Board of Directors...
Vaxart (NASDAQ:VXRT Get Free Report) announced its earnings results on Thursday. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus...
Related Stocks: NAS:VXRT...
Key Financial Highlights and Corporate UpdatesRelated Stocks: VXRT...
Significant progress made in preparing for a Phase 2b study evaluating Vaxart's oral pill XBB COVID-19 vaccine against an approved mRNA vaccine comparator Topline data from Phase 1 norovirus study...
Vaxart FY 2023 Earnings Preview...